The present disclosure relates generally to medical devices, and, more particularly, to an ablation device configured to achieve simultaneous resection and coagulation, or hemostatic sealing, of a tissue.
There are many medical procedures in which tissue is cut or carved away for diagnostic or therapeutic reasons. For example, during hepatic transection, one or more lobes of a liver containing abnormal tissue, such as malignant tissue or fibrous tissue caused by cirrhosis, are cut away. There are a number of available electrosurgical devices for carrying out resection of tissue. However, regardless of the electrosurgical device used, extensive bleeding can occur, which can obstruct the surgeon's view and lead to dangerous blood loss levels, requiring transfusion of blood, which increases the complexity, time, and expense of the resection procedure.
In order to prevent extensive bleeding or accumulation of fluid, hemostatic mechanisms, such as blood inflow occlusion, coagulants, as well as energy coagulation (e.g., electrosurgical coagulation or argon-beam coagulation) can be used. Unlike resection, which involves application of highly intense and localized heating sufficient enough to break intercellular bonds, energy coagulation of tissue involves the application of low level current that denatures cells to a sufficient depth without breaking intercellular bonds, i.e., without cutting the tissue.
Because of their natural coagulation capability, ease of use, and ubiquity, electrosurgical modalities may be used to resect tissue. However, when electrosurgically resecting tissue, care must be taken to prevent the heat generated by the electrode from charring the tissue, which generates an undesirable odor, results in tissue becoming stuck on the electrosurgical probe, and most importantly, increases tissue resistance, thereby reducing the efficiency of the procedure. Current electrosurgical modalities, however, may generally lack the ability to be selectively and efficiently operated in a resecting mode and a coagulation mode, or both, so as to effectively resect tissue, while preventing tissue charring and maintaining hemostasis at the treatment site.
The present invention relates to an ablation device configured to achieve both resection and coagulation of tissue. The ablation device can be used during an electrosurgical resection procedure to both resect tissue and further selectively coagulate surrounding tissue in the resection site so as to prevent or stop fluid accumulation (e.g., blood from vessel(s)) as a result of the resection of tissue. Accordingly, the ablation device of the present invention may be particularly useful in procedures involving the removal of unhealthy, or otherwise undesired, tissue from any part of the body in which resection may be beneficial. Thus, tumors, both benign and malignant, may be removed via surgical intervention with an ablation device described herein.
The tissue ablation device of the present invention generally includes a probe including an elongated shaft configured as a handle and adapted for manual manipulation and a nonconductive distal portion, or distal tip, coupled to the shaft. The nonconductive distal tip includes an electrode array configured to operate in a coagulation mode. The electrode array is composed of a plurality of conductive wires, wherein one or more of the wires may receive energy in the form of electrical current from a source (e.g., RF generator) and emit RF energy in response, resulting in coagulation of tissue in contact therewith. The nonconductive distal tip further includes a single cutting, or resecting, conductive wire. The cutting wire is configured to receive energy in the form of electrical current from the source (e.g., RF generator) and emit RF energy in response, thereby resulting in the resection of a tissue. The device may include a device controller, for example, configured to selectively control the supply of electrical current to the coagulation electrode array and the cutting wire, thereby allowing the device to operate in a cutting mode, a coagulation mode, or both such that the device can simultaneously resect and coagulate tissue at the target site.
The ability of the device to provide both resection and coagulation of tissue is dependent, not only on the nature of the electrical energy delivered to the conductive wires of the electrode array or the single cutting wire, but also on the geometry of the conductive wires along the nonconductive tip. The smaller the surface area of an electrode in proximity to the tissue, the greater the current density of an electrical arc generated by the electrode, and thus the more intense the thermal effect, thereby cutting the tissue. In contrast, the greater the surface area of the electrode in proximity to the tissue, the less the current density of the electrical arc generated by the electrode, thereby coagulating the tissue.
As such, the distal tip has a specific geometry that plays an important role in determining the current density (i.e., the amount of current distributed over an area) of energy emitted by the electrode array and cutting wire. In particular, the distal tip includes at least two opposing sides or faces sharing a common distal-facing edge. Each of the opposing sides of the distal tip includes a generally planar surface providing a relatively large surface area upon which the electrode array is positioned. The distal-facing edge has a leading end and a trailing end, wherein the leading end extends further from the distal tip than the trailing end. The cutting wire is positioned along, and generally follows the length of, the distal-facing edge. Accordingly, a portion of the cutting wire adjacent to the leading end of the edge has a relatively small surface area (when compared to the electrode array surface area) forming an energy focusing portion. Thus, because of the arrangement of the cutting wire along the distal-facing edge, including the energy-focusing portion at the leading end of the edge, the cutting wire can be placed in proximity to the tissue and cut the tissue. In contrast, positioning of the coagulation electrode array on the relatively large surface area of the planar sides or faces of the distal tip allows the electrode array to coagulate tissue.
The ablation device of the present invention is further configured to provide a conductive fluid, such as saline, to the distal tip, which may include one or more ports (e.g., ports through which conductive wires are threaded, additional fluid ports, etc.). The saline weeping through the ports and to an outer surface of the distal tip is able to carry electrical current from electrode array and/or the cutting wire, such that energy is transmitted from the electrode array, or cutting wire, to the tissue by way of the saline weeping from the ports, thereby creating a virtual electrode. Accordingly, upon the fluid weeping through the ports, a pool or thin film of fluid is formed on the exterior surface of the distal tip and is configured to resect and/or coagulate surrounding tissue via the electrical current carried from the electrode array.
Features and advantages of the claimed subject matter will be apparent from the following detailed description of embodiments consistent therewith, which description should be considered with reference to the accompanying drawings, wherein:
For a thorough understanding of the present disclosure, reference should be made to the following detailed description, including the appended claims, in connection with the above-described drawings. Although the present disclosure is described in connection with exemplary embodiments, the disclosure is not intended to be limited to the specific forms set forth herein. It is understood that various omissions and substitutions of equivalents are contemplated as circumstances may suggest or render expedient.
By way of overview, the present disclosure is generally directed to a tissue ablation system including an ablation device to be delivered to a target site and achieve both resection and coagulation of tissue. The ablation device can be used during an electrosurgical resection procedure to both resect tissue and further selectively coagulate surrounding tissue in the resection site so as to prevent or stop fluid accumulation (e.g., blood from vessel(s)) as a result of the resection of tissue. Accordingly, the ablation device of the present invention may be particularly useful in procedures involving the removal of unhealthy, or otherwise undesired, tissue from any part of the body in which resection may be beneficial. Thus, tumors, both benign and malignant, may be removed via surgical intervention with an ablation device described herein.
The tissue ablation device of the present invention generally includes a probe including an elongated shaft configured as a handle and adapted for manual manipulation and a nonconductive distal portion (also referred to herein as “distal tip”) coupled to the shaft. The nonconductive distal tip includes an electrode array configured to operate in a coagulation mode. The electrode array is composed of a plurality of conductive wires, wherein one or more of the wires may receive energy in the form of electrical current from a source (e.g., RF generator) and emit RF energy in response, resulting in coagulation of tissue in contact therewith. The nonconductive distal tip further includes a single cutting, or resecting, conductive wire. The cutting wire is configured to receive energy in the form of electrical current from the source (e.g., RF generator) and emit RF energy in response, thereby resulting in the resection of a tissue. The device may include a device controller, for example, configured to selectively control the supply of electrical current to the coagulation electrode array and the cutting wire, thereby allowing the device to operate in a cutting mode, a coagulation mode, or both such that the device can simultaneously resect and coagulate tissue at the target site.
The ability of the device to provide both resection and coagulation of tissue is dependent, not only on the nature of the electrical energy delivered to the conductive wires of the electrode array or the single cutting wire, but also on the geometry of the conductive wires along the nonconductive tip. The smaller the surface area of an electrode in proximity to the tissue, the greater the current density of an electrical arc generated by the electrode, and thus the more intense the thermal effect, thereby cutting the tissue. In contrast, the greater the surface area of the electrode in proximity to the tissue, the less the current density of the electrical arc generated by the electrode, thereby coagulating the tissue.
As such, the distal tip has a specific geometry that plays an important role in determining the current density (i.e., the amount of current distributed over an area) of energy emitted by the electrode array and cutting wire. In particular, the distal tip includes at least two opposing sides or faces sharing a common distal-facing edge. Each of the opposing sides of the distal tip includes a generally planar surface providing a relatively large surface area upon which the electrode array is positioned. The distal-facing edge has a leading end and a trailing end, wherein the leading end extends further from the distal tip than the trailing end. The cutting wire is positioned along, and generally follows the length of, the distal-facing edge. Accordingly, a portion of the cutting wire adjacent to the leading end of the edge has a relatively small surface area (when compared to the electrode array surface area) forming an energy focusing portion. Thus, because of the arrangement of the cutting wire along the distal-facing edge, including the energy-focusing portion at the leading end of the edge, the cutting wire can be placed in proximity to the tissue and cut the tissue. In contrast, positioning of the coagulation electrode array on the relatively large surface area of the planar sides or faces of the distal tip allows the electrode array to coagulate tissue.
The ablation device of the present invention is further configured to provide a conductive fluid, such as saline, to the distal tip, which may include one or more ports (e.g., ports through which conductive wires are threaded, additional fluid ports, etc.). The saline weeping through the ports and to an outer surface of the distal tip is able to carry electrical current from electrode array and/or the cutting wire, such that energy is transmitted from the electrode array, or cutting wire, to the tissue by way of the saline weeping from the ports, thereby creating a virtual electrode. Accordingly, upon the fluid weeping through the ports, a pool or thin film of fluid is formed on the exterior surface of the distal tip and is configured to resect and/or coagulate surrounding tissue via the electrical current carried from the electrode array.
The devices and systems of the present disclosure can help to ensure that target tissue can be removed via resection while further providing a coagulation capability for addressing any fluid accumulation issues or extensive bleeding as a result of the resection, thereby improving a surgeon's ability to carry out the resection procedure. For example, when a blood vessel is encountered, RF energy can be applied via the electrode array operating in the coagulation mode, so as to shrink the collagen in the blood vessel, thereby closing the blood lumen and achieving hemostasis. In some instances, the cutting wire may be used to hemostatically seal smaller blood vessels (e.g., less than 3 mm in diameter). For example, hemostasis may be achieved via the cutting wire, for example, by utilizing the energy-focusing point in contact with the blood vessel. During or after resection of the tissue, RF energy can be applied to any “bleeders” (i.e., vessels from which blood flows or oozes) to provide complete hemostasis for the resected organ.
The device controller 18 may include hardware/software configured to provide a user with the ability to control electrical output to the ablation device 14 in a manner so as to control the resection or coagulation of tissue. For example, as will be described in greater detail herein, the ablation device may be configured to operate in a “cutting mode”, a “coagulation mode”, or both modes simultaneously depending on input from a user. In some embodiments, the ablation device may be configured to operate in other modes, in addition to the “cutting” and “coagulation” modes. For example, in some embodiments, the device may be configured to operate in a “measurement mode” in which data can be collected, such as certain measurements (e.g., temperature, conductivity (impedance), etc.) can be taken and further used by the controller 18 so as to provide an estimation of the state of tissue during a electrosurgical resection procedure, as will be described in greater detail herein.
Further still, the device controller 18 may include a custom ablation shaping (CAS) system configured to provide a user with custom ablation shaping, which includes the creation of custom, user-defined ablation geometries or profiles from the ablation device 14. The CAS system may further be configured to provide ablation status mapping based on real-time data collection (e.g., measurements) collected by the device, wherein such a CAS system is described in co-pending U.S. application Ser. No. 15/419,269, filed Jan. 30, 2017, the entirety of which is incorporated by reference herein. In some cases, the device controller 18 may be housed within the ablation device 14. The ablation generator 20 may also connected to a return electrode that is attached to the skin of the patient 12.
As will be described in greater detail herein, during a resection procedure, the ablation generator 20 may generally provide RF energy (e.g., electrical energy in the radiofrequency (RF) range (e.g., 350-800 kHz)) to an electrode array of the ablation device 14, as controlled by the device controller 18. At the same time, saline may also be released from the distal tip 16. The RF energy travels through the blood and tissue of the patient 12 to the return electrode and, in the process, ablates the region(s) of tissues adjacent to portions of the electrode array that have been activated.
In some examples, the ablation device 14 may further include a user interface 28 serving as the device controller 18 and in electrical communication with the ablation generator 20 and the ablation device 14. The user interface 28 may include, for example, selectable buttons 30a, 30b for providing a user with one or more operating modes with respect to controlling the resection and coagulation output of the device 14, as will be described in greater detail herein. For example, the selectable buttons 30a, 30b allow a user to control electrical output to the ablation device 14 in a manner so as to control the resection or coagulation of tissue, such that selection of button 30a results in a cutting mode (e.g., energizing cutting wire) and selection of button 30b results in a coagulation mode (energizing electrode array).
The nonconductive distal tip includes an electrode array 40 configured to operate in a coagulation mode and a single and separate cutting, or resecting, conductive wire 42 configured to operate in a cutting mode. The electrode array 40 is generally composed of a plurality of conductive wires (shown as four separate conductive wires), wherein one or more of the wires may receive energy in the form of electrical current from the RF generator 20 and emit RF energy in response, resulting in coagulation of tissue in contact therewith. The cutting wire 42 is configured to receive energy in the form of electrical current from the source (e.g., RF generator) and emit RF energy in response, thereby resulting in the resection of a tissue. As previously described, a user need only provide input (e.g., select one of buttons 30a, 30b) so as to operate the ablation device 14 in the cutting mode, coagulation mode, or both, in which a supply of electrical current is provided to the cutting wire 42 or one or more of the conductive wires of the coagulation electrode array 40, or both.
The distal tip 16 may include a non-conductive material (e.g., a polyamide) as a layer on at least a portion of an internal surface, an external surface, or both an external and internal surface. In other examples, the tip 16 may be formed from a non-conductive material. Additionally or alternatively, the tip 16 material can include an elastomeric material or a shape memory material. In some embodiments, the tip 16 may be rigid, and thus may maintain a default shape.
The distal tip 16 includes a specific geometry or shape that plays an important role in determining the current density (i.e., the amount of current distributed over an area) of energy emitted by the electrode array 40 and cutting wire 42. The ability of the device 14 to provide both resection and coagulation of tissue is dependent, not only on the nature of the electrical energy delivered to the conductive wires of the electrode array 40 or the single cutting wire 42, but also on the geometry of the conductive wires along the tip 16. The smaller the surface area of an electrode in proximity to the tissue, the greater the current density of an electrical arc generated by the electrode, and thus the more intense the thermal effect, thereby cutting the tissue. In contrast, the greater the surface area of the electrode in proximity to the tissue, the less the current density of the electrical arc generated by the electrode, thereby coagulating the tissue.
It should be noted that other electrode array configurations are contemplated herein. For example, although shown to be arranged in a vertical fashion, the conductive wires of the electrode array 40 may be arranged in a different configuration. For example, in one embodiment, the conductive wires may be positioned substantially parallel to the distal-facing edge 46 or may be oriented at an angle relative to the distal-facing edge 46.
In some embodiments, one or more of the conductive wires can be electrically isolated from one or more of the remaining conductive wires, such that the electrical isolation enables various operation modes for the ablation device 14. For example, ablation energy may be supplied to one or more conductive wires in a bipolar mode, a unipolar mode, or a combination bipolar and unipolar mode. In the unipolar mode, ablation energy is delivered between one or more conductive wires of the electrode array 40 and a return electrode, for example. In bipolar mode, energy is delivered between at least two of the conductive wires, while at least one conductive wire remains neutral. In other words, at least, one conductive wire functions as a grounded conductive wire (e.g., electrode) by not delivering energy over at least one conductive wire.
Since each conductive wire in the electrode array 40 is electrically independent, each conductive wire can be connected in a fashion that allows for impedance measurements using bipolar impedance measurement circuits. For example, the conductive wires can be configured in such a fashion that tetrapolar or guarded tetrapolar electrode configurations can be used. For instance, one pair of conductive wires could function as the current driver and the current return, while another pair of conductive wires could function as a voltage measurement pair. Accordingly, a dispersive ground pad can function as current return and voltage references. Their placement dictate the current paths and thus having multiple references can also benefit by providing additional paths for determining the ablation status of the tissue. The impedance measurement capability of the device is described in co-pending U.S. application Ser. No. 15/337,334, filed on Oct. 28, 2016 and U.S. application Ser. No. 15/419,269, filed Jan. 30, 2017, the entireties of which are incorporated by reference herein.
It should be noted that the ablation device 14 of the present disclosure may include different distal tip geometries or shapes. For example,
As previously described, the ablation device 14 of the present invention is further configured to provide a conductive fluid, such as saline, to the distal tip 16, which may include one or more ports 45 (e.g., ports through which conductive wires are threaded, additional fluid ports, etc.). The saline weeping through the ports 45 and to an outer surface of the distal tip 16 is able to carry electrical current from electrode array 40 and/or the cutting wire 42, such that energy is transmitted from the electrode array 40, or cutting wire 42, to the tissue by way of the saline weeping from the ports, thereby creating a virtual electrode. Accordingly, upon the fluid weeping through the ports, a pool or thin film of fluid is formed on the exterior surface of the distal tip 16 and is configured to resect and/or coagulate surrounding tissue via the electrical current carried from the electrode array.
As generally understood, the distal tip may be formed from two or more pieces configured to be coupled to one another to form the unitary distal tip 16, such as a configuration, including internal components and connections, as described in co-pending U.S. application Ser. No. 15/337,334, filed on Oct. 28, 2016 and U.S. application Ser. No. 15/419,269, filed Jan. 30, 2017, the entireties of which are incorporated by reference herein, the entireties of which are incorporated by reference.
Reference throughout this specification to “one embodiment” or “an embodiment” means that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least one embodiment. Thus, appearances of the phrases “in one embodiment” or “in an embodiment” in various places throughout this specification are not necessarily all referring to the same embodiment. Furthermore, the particular features, structures, or characteristics may be combined in any suitable manner in one or more embodiments.
The terms and expressions which have been employed herein are used as terms of description and not of limitation, and there is no intention, in the use of such terms and expressions, of excluding any equivalents of the features shown and described (or portions thereof), and it is recognized that various modifications are possible within the scope of the claims. Accordingly, the claims are intended to cover all such equivalents.
As used in any embodiment herein, the term “controller”, “module”, “subsystem”, or the like, may refer to software, firmware and/or circuitry configured to perform any of the aforementioned operations. Software may be embodied as a software package, code, instructions, instruction sets and/or data recorded on non-transitory computer readable storage medium. Firmware may be embodied as code, instructions or instruction sets and/or data that are hard-coded (e.g., nonvolatile) in memory devices. “Circuitry”, as used in any embodiment herein, may comprise, for example, singly or in any combination, hardwired circuitry, programmable circuitry such as computer processors comprising one or more individual instruction processing cores, state machine circuitry, and/or firmware that stores instructions executed by programmable circuitry. The controller or subsystem may, collectively or individually, be embodied as circuitry that forms part of a larger system, for example, an integrated circuit (IC), system on-chip (SoC), desktop computers, laptop computers, tablet computers, servers, smart phones, etc.
Any of the operations described herein may be implemented in a system that includes one or more storage mediums having stored thereon, individually or in combination, instructions that when executed by one or more processors perform the methods. Here, the processor may include, for example, a server CPU, a mobile device CPU, and/or other programmable circuitry.
Also, it is intended that operations described herein may be distributed across a plurality of physical devices, such as processing structures at more than one different physical location. The storage medium may include any type of tangible medium, for example, any type of disk including hard disks, floppy disks, optical disks, compact disk read-only memories (CD-ROMs), compact disk rewritables (CD-RWs), and magneto-optical disks, semiconductor devices such as read-only memories (ROMs), random access memories (RAMs) such as dynamic and static RAMs, erasable programmable read-only memories (EPROMs), electrically erasable programmable read-only memories (EEPROMs), flash memories, Solid State Disks (SSDs), magnetic or optical cards, or any type of media suitable for storing electronic instructions. Other embodiments may be implemented as software modules executed by a programmable control device. The storage medium may be non-transitory.
As described herein, various embodiments may be implemented using hardware elements, software elements, or any combination thereof. Examples of hardware elements may include processors, microprocessors, circuits, circuit elements (e.g., transistors, resistors, capacitors, inductors, and so forth), integrated circuits, application specific integrated circuits (ASIC), programmable logic devices (PLD), digital signal processors (DSP), field programmable gate array (FPGA), logic gates, registers, semiconductor device, chips, microchips, chip sets, and so forth.
Reference throughout this specification to “one embodiment” or “an embodiment” means that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least one embodiment. Thus, appearances of the phrases “in one embodiment” or “in an embodiment” in various places throughout this specification are not necessarily all referring to the same embodiment. Furthermore, the particular features, structures, or characteristics may be combined in any suitable manner in one or more embodiments.
The terms and expressions which have been employed herein are used as terms of description and not of limitation, and there is no intention, in the use of such terms and expressions, of excluding any equivalents of the features shown and described (or portions thereof), and it is recognized that various modifications are possible within the scope of the claims. Accordingly, the claims are intended to cover all such equivalents.
This application claims the benefit of, and priority to, U.S. Provisional Application No. 62/301,907, filed Mar. 1, 2016, the content of which is hereby incorporated by reference herein in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
4699147 | Chilson et al. | Oct 1987 | A |
4976711 | Parins et al. | Dec 1990 | A |
4979948 | Geddes et al. | Dec 1990 | A |
5045056 | Behl | Sep 1991 | A |
5100423 | Fearnot | Mar 1992 | A |
5117828 | Metzger et al. | Jun 1992 | A |
5163938 | Kambara | Nov 1992 | A |
5334193 | Nardella | Aug 1994 | A |
5429605 | Richling et al. | Jul 1995 | A |
5471982 | Edwards et al. | Dec 1995 | A |
5472441 | Edwards et al. | Dec 1995 | A |
5486161 | Lax et al. | Jan 1996 | A |
5536267 | Edwards et al. | Jul 1996 | A |
5562720 | Stern et al. | Oct 1996 | A |
5657760 | Ying et al. | Aug 1997 | A |
5672153 | Lax et al. | Sep 1997 | A |
5672173 | Gough et al. | Sep 1997 | A |
5672174 | Gough et al. | Sep 1997 | A |
5683384 | Gough et al. | Nov 1997 | A |
5713942 | Stern et al. | Feb 1998 | A |
5728143 | Gough et al. | Mar 1998 | A |
5772590 | Webster, Jr. | Jun 1998 | A |
5782827 | Gough et al. | Jul 1998 | A |
5827276 | LeVeen et al. | Oct 1998 | A |
5840076 | Swanson et al. | Nov 1998 | A |
5846239 | Swanson et al. | Dec 1998 | A |
5855576 | LeVeen et al. | Jan 1999 | A |
5863290 | Gough et al. | Jan 1999 | A |
5868736 | Swanson et al. | Feb 1999 | A |
5868776 | Wright | Feb 1999 | A |
5871483 | Jackson et al. | Feb 1999 | A |
5888198 | Eggers et al. | Mar 1999 | A |
5891136 | McGee et al. | Apr 1999 | A |
5893847 | Kordis | Apr 1999 | A |
5913855 | Gough et al. | Jun 1999 | A |
5928229 | Gough et al. | Jul 1999 | A |
5935123 | Edwards et al. | Aug 1999 | A |
5961513 | Swanson et al. | Oct 1999 | A |
5980517 | Gough | Nov 1999 | A |
6009877 | Edwards | Jan 2000 | A |
6032077 | Pomeranz | Feb 2000 | A |
6036689 | Tu et al. | Mar 2000 | A |
6053913 | Tu et al. | Apr 2000 | A |
6053937 | Edwards et al. | Apr 2000 | A |
6063081 | Mulier et al. | May 2000 | A |
6071278 | Panescu et al. | Jun 2000 | A |
6071280 | Edwards et al. | Jun 2000 | A |
6099526 | Whayne et al. | Aug 2000 | A |
6112123 | Kelleher et al. | Aug 2000 | A |
6123718 | Tu et al. | Sep 2000 | A |
6142993 | Whayne et al. | Nov 2000 | A |
6221071 | Sherry et al. | Apr 2001 | B1 |
6241666 | Pomeranz et al. | Jun 2001 | B1 |
6251109 | Hassett et al. | Jun 2001 | B1 |
6258087 | Edwards et al. | Jul 2001 | B1 |
6309352 | Oraevsky et al. | Oct 2001 | B1 |
6312408 | Eggers | Nov 2001 | B1 |
6312429 | Burbank et al. | Nov 2001 | B1 |
6358248 | Mulier et al. | Mar 2002 | B1 |
6379353 | Nichols | Apr 2002 | B1 |
6409722 | Hoey et al. | Jun 2002 | B1 |
6425877 | Edwards | Jul 2002 | B1 |
6454766 | Swanson et al. | Sep 2002 | B1 |
6491710 | Satake | Dec 2002 | B2 |
6494902 | Hoey et al. | Dec 2002 | B2 |
6503247 | Swartz et al. | Jan 2003 | B2 |
6522930 | Schaer et al. | Feb 2003 | B1 |
6537248 | Mulier et al. | Mar 2003 | B2 |
6537272 | Christopherson et al. | Mar 2003 | B2 |
6544262 | Fleischman | Apr 2003 | B2 |
6551310 | Ganz et al. | Apr 2003 | B1 |
6585732 | Mulier et al. | Jul 2003 | B2 |
6623481 | Garbagnati et al. | Sep 2003 | B1 |
6638275 | McGaffigan et al. | Oct 2003 | B1 |
6648883 | Francischelli et al. | Nov 2003 | B2 |
6663622 | Foley et al. | Dec 2003 | B1 |
6692466 | Chow et al. | Feb 2004 | B1 |
6736810 | Hoey et al. | May 2004 | B2 |
6736811 | Panescu et al. | May 2004 | B2 |
6743226 | Cosman et al. | Jun 2004 | B2 |
6764487 | Mulier et al. | Jul 2004 | B2 |
6770072 | Truckai et al. | Aug 2004 | B1 |
6780183 | Jimenez, Jr. et al. | Aug 2004 | B2 |
6805131 | Kordis | Oct 2004 | B2 |
6826421 | Beatty et al. | Nov 2004 | B1 |
6849073 | Hoey et al. | Feb 2005 | B2 |
6872206 | Edwards et al. | Mar 2005 | B2 |
6878149 | Gatto | Apr 2005 | B2 |
6955641 | Lubock | Oct 2005 | B2 |
6978788 | Klimberg et al. | Dec 2005 | B2 |
6984232 | Vanney et al. | Jan 2006 | B2 |
7104989 | Skarda | Sep 2006 | B2 |
7150745 | Stern et al. | Dec 2006 | B2 |
7156845 | Mulier et al. | Jan 2007 | B2 |
7169144 | Hoey et al. | Jan 2007 | B2 |
7247155 | Hoey et al. | Jul 2007 | B2 |
7276061 | Schaer et al. | Oct 2007 | B2 |
7306593 | Keidar et al. | Dec 2007 | B2 |
7326208 | Vanney et al. | Feb 2008 | B2 |
7344535 | Stern et al. | Mar 2008 | B2 |
7364579 | Mulier et al. | Apr 2008 | B2 |
7367972 | Francischelli et al. | May 2008 | B2 |
7371231 | Rioux et al. | May 2008 | B2 |
7399299 | Daniel et al. | Jul 2008 | B2 |
7416552 | Paul et al. | Aug 2008 | B2 |
7419489 | Vanney et al. | Sep 2008 | B2 |
7556628 | Utley et al. | Jul 2009 | B2 |
7632268 | Edwards et al. | Dec 2009 | B2 |
7717909 | Strul et al. | May 2010 | B2 |
7769432 | Klimberg et al. | Aug 2010 | B2 |
7776034 | Kampa | Aug 2010 | B2 |
7828793 | Thompson et al. | Nov 2010 | B2 |
7862498 | Nguyen et al. | Jan 2011 | B2 |
7879030 | Paul et al. | Feb 2011 | B2 |
7942873 | Kwan et al. | May 2011 | B2 |
7959628 | Schaer et al. | Jun 2011 | B2 |
7959631 | DiCarlo | Jun 2011 | B2 |
8034022 | Boatman | Oct 2011 | B2 |
8043289 | Behl et al. | Oct 2011 | B2 |
8048069 | Skwarek et al. | Nov 2011 | B2 |
8114071 | Woloszko et al. | Feb 2012 | B2 |
8224416 | de la Rama et al. | Jul 2012 | B2 |
8303584 | Burdio Pinilla et al. | Nov 2012 | B2 |
8388573 | Cox | Mar 2013 | B1 |
8398624 | Rioux et al. | Mar 2013 | B2 |
8409193 | Young et al. | Apr 2013 | B2 |
8444638 | Woloszko et al. | May 2013 | B2 |
8465484 | Davalos et al. | Jun 2013 | B2 |
8465486 | Danek et al. | Jun 2013 | B2 |
8588886 | de la Rama et al. | Nov 2013 | B2 |
8591461 | Boatman | Nov 2013 | B2 |
8617158 | Garabedian et al. | Dec 2013 | B2 |
8647339 | Satake | Feb 2014 | B2 |
8657814 | Werneth et al. | Feb 2014 | B2 |
8734439 | Gough et al. | May 2014 | B2 |
8814855 | DiCarlo et al. | Aug 2014 | B2 |
8834461 | Werneth et al. | Sep 2014 | B2 |
8979838 | Woloszko | Mar 2015 | B2 |
8979841 | Kunis et al. | Mar 2015 | B2 |
9078665 | Moss et al. | Jul 2015 | B2 |
9131980 | Bloom | Sep 2015 | B2 |
9839472 | Rioux et al. | Dec 2017 | B2 |
9848936 | Rioux et al. | Dec 2017 | B2 |
9855098 | Rioux | Jan 2018 | B2 |
20010031941 | Edwards et al. | Oct 2001 | A1 |
20020026186 | Woloszko et al. | Feb 2002 | A1 |
20020062123 | McClurken et al. | May 2002 | A1 |
20020087208 | Koblish et al. | Jul 2002 | A1 |
20020095152 | Ciarrocca | Jul 2002 | A1 |
20020115992 | Utley et al. | Aug 2002 | A1 |
20020120259 | Lettice | Aug 2002 | A1 |
20020120267 | Phan | Aug 2002 | A1 |
20020128641 | Underwood et al. | Sep 2002 | A1 |
20030009166 | Moutafis et al. | Jan 2003 | A1 |
20030036680 | Black | Feb 2003 | A1 |
20030130711 | Pearson et al. | Jul 2003 | A1 |
20030216725 | Woloszko et al. | Nov 2003 | A1 |
20030225403 | Woloszko et al. | Dec 2003 | A1 |
20040087936 | Stern et al. | May 2004 | A1 |
20040092960 | Abrams et al. | May 2004 | A1 |
20050049454 | Ouchi | Mar 2005 | A1 |
20050070894 | McClurken | Mar 2005 | A1 |
20050154386 | West et al. | Jul 2005 | A1 |
20050187491 | Burbank | Aug 2005 | A1 |
20060212032 | Daniel et al. | Sep 2006 | A1 |
20060259027 | Kwan | Nov 2006 | A1 |
20070083195 | Werneth et al. | Apr 2007 | A1 |
20080004534 | Gelbart et al. | Jan 2008 | A1 |
20080015565 | Davison | Jan 2008 | A1 |
20080103494 | Rioux et al. | May 2008 | A1 |
20080140001 | Globerman et al. | Jun 2008 | A1 |
20080234673 | Marion | Sep 2008 | A1 |
20090171340 | Young | Jul 2009 | A1 |
20090248021 | McKenna | Oct 2009 | A1 |
20090292177 | Eggers et al. | Nov 2009 | A1 |
20090299355 | Bencini et al. | Dec 2009 | A1 |
20100114087 | Edwards et al. | May 2010 | A1 |
20100256629 | Wylie et al. | Oct 2010 | A1 |
20100292689 | Davison et al. | Nov 2010 | A1 |
20110172485 | Lubock | Jul 2011 | A1 |
20110257646 | Utley et al. | Oct 2011 | A1 |
20120029510 | Haverkost | Feb 2012 | A1 |
20120059437 | Shalev | Mar 2012 | A1 |
20120109250 | Cates et al. | May 2012 | A1 |
20120172680 | Gelfand et al. | Jul 2012 | A1 |
20130085493 | Bloom et al. | Apr 2013 | A1 |
20130158536 | Bloom | Jun 2013 | A1 |
20130172870 | Germain et al. | Jul 2013 | A1 |
20130184702 | Neal, II et al. | Jul 2013 | A1 |
20130184706 | Gelbart et al. | Jul 2013 | A1 |
20130253506 | Rioux et al. | Sep 2013 | A1 |
20130310833 | Brown | Nov 2013 | A1 |
20130338662 | Weber | Dec 2013 | A1 |
20140018788 | Engelman et al. | Jan 2014 | A1 |
20140018794 | Anderson et al. | Jan 2014 | A1 |
20140031810 | Mahvi et al. | Jan 2014 | A1 |
20140058376 | Horn et al. | Feb 2014 | A1 |
20140221998 | Latterell | Aug 2014 | A1 |
20140276731 | Voegele et al. | Sep 2014 | A1 |
20140276748 | Ku | Sep 2014 | A1 |
20140378960 | Fischer | Dec 2014 | A1 |
20150018817 | Willard | Jan 2015 | A1 |
20150141982 | Lee | May 2015 | A1 |
20160113707 | Sahakian et al. | Apr 2016 | A1 |
20160113708 | Moss et al. | Apr 2016 | A1 |
20160184008 | Papaioannou et al. | Jun 2016 | A1 |
20160317221 | Rioux | Nov 2016 | A1 |
20170000559 | Rioux et al. | Jan 2017 | A1 |
20170027633 | Wham et al. | Feb 2017 | A1 |
20170119454 | Rioux et al. | May 2017 | A1 |
20170172646 | Patel | Jun 2017 | A1 |
20170215947 | Rioux et al. | Aug 2017 | A1 |
20170215951 | Wang et al. | Aug 2017 | A1 |
20170281267 | Rioux et al. | Oct 2017 | A1 |
20170281271 | Rioux | Oct 2017 | A1 |
20180014880 | Rioux et al. | Jan 2018 | A1 |
20180078305 | Rioux et al. | Mar 2018 | A1 |
20180104004 | Rioux et al. | Apr 2018 | A1 |
Number | Date | Country |
---|---|---|
2610858 | Apr 2004 | CN |
104546124 | Apr 2015 | CN |
102010032932 | Feb 2012 | DE |
0777445 | Jun 1999 | EP |
2942023 | Feb 2016 | EP |
3040043 | Jan 2018 | EP |
3009735 | Feb 2000 | JP |
9510326 | Apr 1995 | WO |
9942047 | Aug 1999 | WO |
0051683 | Sep 2000 | WO |
2007103986 | Sep 2007 | WO |
2011143468 | Nov 2011 | WO |
2012015722 | Feb 2012 | WO |
2012050637 | Apr 2012 | WO |
2014022379 | Feb 2014 | WO |
2014189887 | Nov 2014 | WO |
2015142674 | Sep 2015 | WO |
2015163846 | Oct 2015 | WO |
2015200518 | Dec 2015 | WO |
2016181318 | Nov 2016 | WO |
Entry |
---|
International Search Report and Written Opinion of the International Searching Authority dated Oct. 19, 2017 for International Application No. PCT/US2017/041501 (63 Pages). |
Extended European Search Report dated Jun. 10, 2016 for European Application No. 13825361.2 (13 Pages). |
International Search Report and Written Opinion of the International Searching Authority dated May 16, 2017 for International Application No. PCT/US2017/015582 (11 pages). |
International Search Report and Written Opinion of the International Searching Authority dated Aug. 22, 2016 for International Application No. PCT/US2016/030081 (11 Pages). |
International Search Report and Written Opinion of the International Searching Authority dated Aug. 5, 2015 for International Application No. PCT/US2015/020596 (13 Pages). |
International Search Report and Written Opinion of the International Searching Authority dated Nov. 29, 2013 or International Application No. PCT/US2013/052703 (11 Pages). |
International Search Report and Written Opinion of the International Searching Authority dated Feb. 2, 2017 for International Application No. PCT/US2016/059345 (10 Pages). |
International Search Report and Written Opinion of the International Searching Authority dated May 16, 2017 for International Application No. PCT/US2017/015584 (11 pages). |
“Aquamantys System” Product Brochure, Medtronic, 2014 (12 Pages). |
“Starburst Talon” Specifications Brochure, Angiodynamics, 2013 (2 Pages). |
Medtronic, “Aquamantys Bipolar Sealers.” Electrosurgical Products, Jun. 2017. Retrieved Jul. 21, 2017. <http://www.medtronic.com/us-en/healthcare-professionals/products/general-surgery/electrosurgical/aquamantys-bipolar-sealers.html> (11 Pages). |
International Search Report and Written Opinion of the International Searching Authority dated Nov. 1, 2018 for International Application No. PCT/US2018/043654 (10 Pages). |
International Search Report and Written Opinion of the International Searching Authority dated Nov. 15, 2018 for International Application PCT/US2018/043658 (15 Pages). |
Notice of Allowance dated Jul. 24, 2018 for U.S. Appl. No. 15/784,778 (12 Pages). |
International Search Report and Written Opinion of the International Searching Authority dated Aug. 26, 2018 for International Application No. PCT/US2017/059850 (10 Pages). |
International Search Report and Written Opinion of the Interational Searching Authority dated Feb. 27, 2018 for International Application No. PCT/US2017/056754 (11 Pages). |
Non-Final Office Action dated May 7, 2018 for U.S. Appl. No. 15/142,616 (13 Pages). |
International Search Report and Written Opinion dated Jun. 6, 2018 for International Application No. PCT/US2018/019151 (17 Pages). |
International Search Report and Written Opinion of the International Searching Authority dated Sep. 16, 2018 for International Application No. PCT/US2018/036268 (11 Pages). |
International Search Report and Written Opinion of the International Searching Authority dated Jun. 11, 2017 for International Application No. PCT/US2017/019398 (27 Pages). |
Non-Final Office Action dated Aug. 11, 2017 for U.S. Appl. No. 15/337,334 (11 Pages). |
Response to Non-Final Office Action Filed Sep. 20, 2017 for U.S. Appl. No. 15/337,334 (6 Pages). |
Non-Final Office Action dated Aug. 11, 2017 for U.S. Appl. No. 15/624,327 (11 Pages). |
Response to Non-Final Office Action Filed Sep. 19, 2017 for U.S. Appl. No. 15/624,327 (8 Pages). |
Non-Final Office Action dated Aug. 4, 2017 for U.S. Appl. No. 15/624,230 (18 Pages). |
Response to Non-Final Office Action Filed Sep. 20, 2017 for U.S. Appl. No. 15/624,230 (10 Pages). |
Extended European Search Report issued in European Application No. 16787228.2, dated Nov. 27, 2018, 6 pages. |
Extended European Search Report issued in European Application No. 16860886.7, dated Jun. 12, 2019, 8 pages. |
Extended European Search Report issued in European Application No. 17747970.6, dated Jul. 16, 2019, 6 pages. |
Extended European Search Report issued in European Application No. 17828289.3, dated Feb. 6, 2020, 5 pages. |
Extended European Search Report issued in European Application No. 17895158.8, dated Feb. 28, 2020, 8 pages. |
Extended European Search Report issued in European Application No. 19219030.4, dated Jun. 26, 2020, 6 pages. |
Official Action issued in Japanese Patent Application No. 2018-540040, dated Jun. 19, 2019, 11 pages. |
Number | Date | Country | |
---|---|---|---|
20170252092 A1 | Sep 2017 | US |
Number | Date | Country | |
---|---|---|---|
62301907 | Mar 2016 | US |